Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for Lexeo Therapeutics, Inc. Common Stock (LXEO).
- Disclosed ownership: 5.5%.
- Date of event: 31 Dec 2024.
BlackRock, Inc. - 31 Dec 2024 SCHEDULE 13G Report for Lexeo Therapeutics, Inc. Common Stock (LXEO)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- LXEO
- Shares outstanding
- 33,126,655 shares
- Disclosed Ownership
- 1,821,966 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G
- Filing time
- 04 Feb 2025, 15:45:44 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 17 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.5% ownership in Lexeo Therapeutics, Inc. Common Stock (LXEO) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 04 Feb 2025, 15:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.5% | 1,821,966 | 1,804,571 | 0 | Spencer Fleming | Managing Director |